Sucampo to be Added to the NASDAQ Biotechnology Index
BETHESDA, Md. -- May 15, 2013
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that NASDAQ
OMX Group, Inc. (NASDAQ: NDAQ) will include the company in the NASDAQ
Biotechnology Index^® (NASDAQ: NBI) effective prior to market open on Monday,
May 20, 2013.
The NASDAQ Biotechnology Index is designed to track the performance of a set
of securities listed on The NASDAQ Stock Market that are classified as either
biotechnology or pharmaceutical according to the Industry Classification
Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market
capitalization weighted index. Among the various criteria that must be met in
order to be eligible for inclusion in this index are a market capitalization
of at least $200 million and an average daily trading volume of at least
100,000 shares. The NASDAQ Biotechnology Index is re-ranked semi-annually in
May and November.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please
AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the
tagline, The Science of Innovation, are registered trademarks of Sucampo AG.
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
Press spacebar to pause and continue. Press esc to stop.